ArticleACS biomaterials science & engineering2017
Article in ACS biomaterials science & engineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 88 citations in OpenAlex.
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Review
- Microneedle-Assisted Cell Delivery and Therapy.Research (Washington, D.C.) · 2026Review
- Bioengineered microneedles and nanomedicine as therapeutic platform for tissue regeneration.Journal of nanobiotechnology · 2025Review
- Advancing Melanoma Care: Microneedles for Diagnosis and Therapeutic Precision.Current pharmaceutical design · 2025Review
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Microneedle array delivery ofiScience · 2024Article
- Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.ACS applied bio materials · 2023Review
- Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.Nano-micro letters · 2023Review
- Microneedle-mediated treatment for superficial tumors by combining multiple strategies.Drug delivery and translational research · 2023Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Tuning innate immune function using microneedles containing multiple classes of toll-like receptor agonists.Nanoscale · 2023Article
- Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Metallic elements combine with herbal compounds upload in microneedles to promote wound healing: a review.Frontiers in bioengineering and biotechnology · 2023Review
- Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy.Drug delivery · 2022Article
- Novel Pharmaceutical Strategies for Enhancing Skin Penetration of Biomacromolecules.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recent Advances of Microneedles and Their Application in Disease Treatment.International journal of molecular sciences · 2022Review
- The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.DNA and cell biology · 2022Review
- Mapping the Mechanical and Immunological Profiles of Polymeric Microneedles to Enable Vaccine and Immunotherapy Applications.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Microneedles (MNs) are micron-scale polymeric or metallic structures that offer distinct advantages for vaccines by efficiently targeting skin-resident immune cells, eliminating injection-associated pain, and improving patient compliance. These advantages, along with recent studies showing therapeutic benefits achieved using traditional intradermal injections in human cancer patients, suggest MN delivery might enhance cancer vaccines and immunotherapies. We recently developed a new class of polyelectrolyte multilayers based on the self-assembly of model peptide antigens and molecular toll-like receptor agonists (TLRa) into ultrathin, conformal coatings. Here, we reasoned that these immune polyelectrolyte multilayers (iPEMs) might be a useful platform for assembling cancer vaccine components on MN arrays for intradermal delivery from these substrates. Using conserved human melanoma antigens and a potent TLRa vaccine adjuvant, CpG, we show that iPEMs can be assembled on MNs in an automated fashion. These films, prepared with up to 128 layers, are approximately 200 nm thick but provide cancer vaccine cargo loading >225 μg/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.